FedCircuitBlog

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• an article about “[a] Bristol Myers Squibb Co subsidiary on Monday los[ing] a renewed bid for the U.S. Supreme Court to hear its appeal of a 2021 decision that invalidated its cancer-drug patent and overturned a $1.2 billion infringement award it won”; and
• another article arguing that broad functional patent claims suppress medical innovation.

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• an article about Intel “doubl[ing] down on its Federal Circuit bid to ax a $2.18 billion jury verdict against it”;
• a blog post about a Patent Trial and Appeal Board judge withdrawing from an inter partes review proceeding; and
• another article about the U.S. Patent and Trademark Office making trademark applications related to green technology and climate change eligible for reduced fees.

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• an article about the Federal Circuit allowing Chief U.S. Judge Colm Connolly of the District of Delaware to “inquire into compliance with his standing orders into ownership transparency” in patent cases;
• another article about the Federal Circuit denying a motion to enjoin a litigant “from commercially marketing generic versions of [a] sleep disorder drug”; and
• a third article about a Federal Circuit decision regarding whether under a pretrial discovery order in a patent case is appealable under the collateral order doctrine.

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• an article about pending Supreme Court cases focused on intellectual property; and
• another article about “the five most important developments” in 2022 related to “patents in the pharma and biotech sectors.”

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• an article about the U.S. International Trade Commission finding “Apple Watches with an electrocardiogram (ECG) function infringe patents belonging to medical device maker AliveCor Inc”;
• another article about Amgen Inc.’s arguments to the Supreme Court that “patents needn’t spell out every possible iteration of an invention in order to be eligible for protection”;
• a third article about “VLSI Technology LLC and Intel Corp . . . agree[ing] to end a patent dispute in Delaware”; and
• a fourth article about “[t]he Federal Circuit . . . order[ing] a California company to defend patent litigation it filed in Texas, as its competitor in optical filters is asking to have the case transferred.”

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• a blog post about some of the most common claim drafting issues “for biotech, chemical and pharma patent applications”;
• an article about how “VLSI Technology LLC plans to appeal an administrative ruling that wiped out 12 of its microchip patent claims”; and
• another article about “Jazz Pharmaceuticals Inc. . . . [urging] the Federal Circuit to undo a federal injunction forcing it to delist a narcolepsy drug-related patent.”

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• a blog post about the Federal Circuit granting a petition for writ of mandamus to transfer claims from the Western District of Texas to the District of Colorado;
• an article about the California Institute of Technology urging the Supreme Court “not to take up a $1.1 billion patent infringement dispute between the university and Apple”; and
• another article about the Federal Circuit denying a “motion to stop . . . performance of a $133 million US Navy base operations support services contract.”

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• a blog post about the Federal Circuit “den[ying] a petition for writ of mandamus asking the Delaware district court to vacate an order to produce certain documents” related to third party funding in patent case; and
• an article about “Pfizer and BioNTech[‘s] . . . countersuit, demanding a jury trial and refuting Moderna’s claims of infringement” of patents related to COVID-19 vaccines.

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• a blog post about “requirements for transparency regarding litigation funding and company and/or patent ownership” in the District of Delaware;
• an article about overcoming dismissals under Section 101 of the Patent Act; and
• another article about the Federal Circuit’s decision “reject[ing] a tech company’s bid to transfer a patent case it is facing out of . . . Waco.”

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• an article about a $948 million patent infringement verdict between Intel and VLSI Technology LLC;
• another article about a Federal Circuit decision finding a generic cancer drug infringes on “Abbvie’s Pharmacyclics and Johnson & Johnson’s Janssen Biotech . . . blockbuster cancer drug Imbruvica”; and
• a blog post about a Federal Circuit decision affirming the Patent Trial and Appeal Board’s decision “involving American National Manufacturing and Sleep Number Corp.”